PARAPOXVIRUS VECTORS
The present invention relates to recombinant parapoxviruses comprising heterologous DNA derived from a canine distemper virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates to the use of recombinant parapoxviruses for diagnostics.
1 . A recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a canine distemper virus.
2 . The recombinant parapoxvirus of claim 1 , wherein the parapoxvirus is a Parapoxvirus ovis virus (ORFV).
3 . The recombinant parapoxvirus of claim 2 , wherein the parapoxvirus is Parapoxvirus ovis strain D1701.
4 . The recombinant parapoxvirus of claim 3 , wherein the recombinant parapoxvirus is selected from the group consisting of parapoxvirus ovis D1701-V-CDV-H and parapoxvirus ovis D1701-V-CDV-F.
5 . The recombinant parapoxvirus of claim 1 , wherein the heterologous DNA is selected from the group consisting of the gene encoding the H protein of the canine distemper virus, fragments of said gene encoding the H protein, the gene encoding the F protein of the canine distemper virus, and fragments of said gene encoding the F protein.
6 . The recombinant parapoxvirus of claim 5 , wherein the heterologous DNA is the gene encoding the H protein of the canine distemper virus, or fragments thereof.
7 . The recombinant parapoxvirus of claim 5 , wherein the heterologous DNA is the gene encoding the F protein of the canine distemper virus, or fragments thereof.
8 . The recombinant parapoxvirus of claim 1 , wherein the heterologous DNA is selected from the group consisting of SEQ ID NO: 1, a sequence having at least about 98% identity to SEQ ID NO: 1, SEQ ID NO: 2, and a sequence having at least about 98% identity to SEQ ID NO: 2.
9 . The recombinant parapoxvirus of claim 1 , wherein the heterologous DNA is inserted within the HindIII fragment H/H of Parapoxvirus ovis strain D1701.
10 . The recombinant parapoxvirus of claim 9 , wherein the heterologous DNA is inserted within the VEGF coding sequence or adjacent non-coding sequences within the HindIII fragment H/H of Parapoxvirus ovis strain D1701.
11 . A method of preparing the recombinant parapoxvirus of claim 1 comprising inserting heterologous DNA into the genome of the parapoxvirus.
12 . The method of claim 11 , wherein the parapoxvirus is Parapoxvirus ovis.
13 . The method of claim 11 , wherein the parapoxvirus is Parapoxvirus ovis strain D 1701.
14 . The method of claim 11 , wherein the recombinant parapoxvirus is selected from the group consisting of parapoxvirus ovis D1701-V-CDV-H and parapoxvirus ovis D1701-V-CDV-F.
15 . The method of claim 11 , wherein the heterologous DNA is selected from the group consisting of the gene encoding the H protein of the canine distemper virus, fragments of said gene encoding the H protein, the F protein of the canine distemper virus, and fragments of said gene encoding the F protein.
16 . The method of claim 15 , wherein the heterologous DNA is the gene encoding the H protein of the canine distemper virus, or fragments thereof.
17 . The method of claim 15 , wherein the heterologous DNA is the gene encoding the F protein of the canine distemper virus, or fragments thereof.
18 . The method of claim 11 , wherein the heterologous DNA is selected from the group consisting of SEQ ID NO: 1, a sequence having at least about 98% identity to SEQ ID NO: 1, SEQ ID NO 2, and a sequence having at least about 98% identity to SEQ ID NO: 2.
19 . An immunogenic composition comprising the recombinant parapoxvirus of claim 1 and a carrier.
20 . The immunogenic composition of claim 19 , wherein the parapoxvirus is Parapoxvirus ovis.
21 . The immunogenic composition of claim 20 , wherein the parapoxvirus is Parapoxvirus ovis strain D 1701.
22 . The immunogenic composition of claim 19 , wherein the recombinant parapoxvirus is selected from the group consisting of parapoxvirus ovis D1701-V-CDV-H and parapoxvirus ovis D1701-V-CDV-F.
23 . The immunogenic composition of claim 19 , wherein the heterologous DNA is selected from the group consisting of the gene encoding the H protein of the canine distemper virus, fragments of said gene encoding the H protein, the F protein of the canine distemper virus, and fragments of said gene encoding the F protein.
24 . The immunogenic composition of claim 23 , wherein the heterologous DNA is the gene encoding the H protein of the canine distemper virus, or fragments thereof.
25 . The immunogenic composition of claim 23 , wherein the heterologous DNA is the gene encoding the F protein of the canine distemper virus, or fragments thereof.
26 . The immunogenic composition of claim 19 , wherein the heterologous DNA is selected from the group consisting of SEQ ID NO: 1, a sequence having at least about 98% identity to SEQ ID NO: 1, SEQ ID NO: 2, and a sequence having at least about 98% identity to SEQ ID NO: 2.
27 . A method of preparing the immunogenic composition of claim 19 .
28 . The method of claim 27 , wherein the parapoxvirus is Parapoxvirus ovis.
29 . The method of claim 28 , wherein the parapoxvirus is Parapoxvirus ovis strain D 1701.
30 . The method of claim 27 , wherein the recombinant parapoxvirus is selected from the group consisting of parapoxvirus ovis D1701-V-CDV-H and parapoxvirus ovis D1701-V-CDV-F.
31 . The method of claim 27 , wherein the heterologous DNA is selected from the group consisting of the gene encoding the H protein of the canine distemper virus, fragments of said gene encoding the H protein, the F protein of the canine distemper virus, and fragments of said gene encoding the F protein.
32 . The method of claim 27 , wherein the heterologous DNA is selected from the group consisting of SEQ ID NO: 1, a sequence having at least about 98% identity to SEQ ID NO: 1, SEQ ID NO: 2, and a sequence having at least about 98% identity to SEQ ID NO: 2.
33 . A method of inducing in an animal subject an immune response against canine distemper virus comprising administering to said animal a therapeutically effective amount of the immunogenic composition of claim 19 .
34 . The method of claim 33 , wherein an anti-H or anti-F protein-specific protective immune response is induced.
35 . A method of treating an animal subject against canine distemper disease, comprising administering to said animal a therapeutically effective amount of the immunogenic composition of claim 19 .
36 . Use of the recombinant parapoxvirus of claim 1 in the preparation of a medicament for treating an animal against canine distemper disease.
37 . A use of the recombinant parapoxvirus of claim 1 in an assay for the differentiation of infected from vaccinated animals.
38 . The use of claim 37 , wherein the recombinant parapoxvirus is selected from the group consisting of parapoxvirus ovis D1701-V-CDV-H and parapoxvirus ovis D1701-V-CDV-F.